Long-Term Assessment of Remyelinating Therapy (RENEWED)
A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201
Sponsor: Biogen
Listed as NCT02657915, this PHASE2 trial focuses on Acute Optic Neuritis and remains completed. Sponsored by Biogen, it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2019 — Oct 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Phase: NA → PHASE2
-
Mar 2017 — Mar 2018 [monthly]
Completed NA
Status: Enrolling By Invitation → Completed
-
Feb 2017 — Mar 2017 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bamberg, Germany , Barcelona, Spain , Berlin, Germany , Birmingham, United Kingdom , Bruges, Belgium , Budapest, Hungary , Córdoba, Spain , Dresden, Germany , Düsseldorf, Germany , Glasgow, United Kingdom and 13 more locations